Drugs / CART33
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05945849 | Feb 2024 → Feb 2029 expected | acute myeloid leukemia | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 1 | NCT02799680 | Oct 2015 → May 2017 | acute myeloid leukemia | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02799680 ↗ |
| Action | Deplete | “CAR T-cells that have been engineered to recognize and attack your AML cells” NCT05945849 ↗ |
| Modality | Cell therapy | “allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)” NCT02799680 ↗ |
| Route | Intravenous | “CAR T-cells, which are leukemia fighting cells, which will be given to the patient via an infusion into the vein” NCT05945849 ↗ |
| Target | CD33 | “CD33-directed chimeric antigen receptor-modified T cells” NCT02799680 ↗ |